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Abstract
Intravenous silibinin (SIL) is an approved therapeutic that has recently been applied to patients
with chronic hepatitis C, successfully clearing hepatitis C virus (HCV) infection in some patients
even in monotherapy. Previous studies suggested multiple antiviral mechanisms of SIL, however,
the dominant mode of action has not been determined. We first analyzed the impact of SIL on
replication of subgenomic replicons from different HCV genotypes in vitro and found a strong
inhibition of RNA replication for genotype 1a and genotype 1b. In contrast, RNA replication and
infection of genotype 2a were minimally affected by SIL. To identify the viral target of SIL we
analyzed resistance to SIL in vitro and in vivo. Selection for drug resistance in cell culture
identified a mutation in HCV nonstructural protein (NS) 4B conferring partial resistance to SIL.
This was corroborated by sequence analyses of HCV from a liver transplant recipient experiencing
viral breakthrough under SIL monotherapy. Again, we identified distinct mutations affecting
highly conserved amino acid residues within NS4B, which mediated phenotypic SIL resistance
also in vitro. Analyses of chimeric viral genomes suggest that SIL might target an interaction
between NS4B and NS3/4A. Ultrastructural studies revealed changes in the morphology of viral
membrane alterations upon SIL treatment of a susceptible genotype 1b isolate, but not of a
resistant NS4B mutant or genotype 2a, indicating that SIL might interfere with the formation of
HCV replication sites.
Conclusion—Mutations conferring partial resistance to SIL treatment in vivo and in cell culture
argue for a mechanism involving NS4B. This novel mode of action renders SIL an attractive
*Corresponding author: Volker Lohmann, Department of Infectious Diseases, Molecular Virology, University of Heidelberg, Im
Neuenheimer Feld 345, D-69120 Heidelberg, Germany, Volker_lohmann@med.uni-heidelberg.de, Phone: +49-6221-566449, Fax:
+49-6221-564570.
#Authors contributed equally to this work
The authors have no conflict of interest.
NIH Public Access
Author Manuscript
Hepatology. Author manuscript; available in PMC 2014 March 01.
Published in final edited form as:
Hepatology. 2013 March ; 57(3): 953–963. doi:10.1002/hep.26260.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
candidate for combination therapies with other directly acting antiviral drugs, particularly in
difficult-to-treat patient cohorts.
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Worldwide about 170 million people are chronically infected with HCV, a positive-strand
RNA virus belonging to the Flaviviridae family and leading to severe liver disease in many
cases. Only 50% of the patients respond to therapy with pegylated IFNα (pegIFNα) +
Ribavirin (RBV) for yet unknown reasons. The newly available direct acting antivirals
(DAA) telaprevir and boceprevir enhance sustained viral response rates up to 70–75%
during triple therapy (pegIFNα + RBV + DAA) of genotype 1 infected patients, but are
accompanied by numerous and potentially severe adverse effects (1). Therefore there is still
an urgent need for more potent and better tolerated therapeutic options.
Silymarin is an extract from the milk thistle plant (Silybum marianum) and contains a
mixture of several compounds with silibinin (SbN) being the major component consisting of
the two flavonolignans silybin A and silybin B. In contrast to the oral formulation (2),
succinylated silibinin (Legalon-SIL® (SIL)), which is administered intravenously, has
antiviral effects in chronic HCV patients. This mixture has been primarily used to prevent
re-infection of the graft after liver transplantation (3–5) and for the treatment of IFNα/RBV
nonresponders (6–9). Importantly, several individual case reports showed that patients could
even be cured from HCV by SIL monotherapy with few adverse side effects, underlining the
antiviral potency of this therapeutic (3–5). However, the mode of action (MOA) of SIL is
currently under debate. Ahmed-Belkacem et al. (10) suggested that SIL targets viral RNA
replication by direct inhibition of the HCV RNA dependent RNA polymerase (RdRp).
Wagoner et al. (11) observed an efficient block of viral RNA replication of HCV genotype
1b (gt1b) replicons by SIL as well, accompanied by additional effects of SIL on viral entry
as well as progeny virus particle production at very high SIL concentrations. In this study
we aimed to clarify the MOA of SIL by analyzing the effect of SIL on the replication of
different viral genotypes as well as emergence of SIL-resistant viruses in vitro and in vivo.
Experimental Procedures
Reagents
Legalon SIL® (SIL) (lyophilized, Madaus, Cologne) was resuspended to 28.5mg/ml
(corresponding to 67.6mM) in sterile water and stored at −70°C. Further dilution was carried
out in complete DMEM.
Cell culture and viruses
All amino acid and nucleotide numbers refer to the position of the corresponding amino acid
in the complete HCV genomes of JFH1, Con1 and H77 (GenBank accession no. AB047639,
AJ238799 and AF011751, respectively). Detailed information can be found in
Supplementary Materials and Methods.
SIL-treatment
SIL was diluted in complete DMEM to concentrations ranging from 1μM to 1mM. In assays
based on transient transfection of replicon RNA or stable replicon cells SIL treatment
occurred 4h after seeding of the cells until cell lysis at 48h. In the infection assay with
JcR-2a the drug was added together with the virus. At 6h post infection, medium was
replaced with fresh medium containing SIL and incubated for 48h. In transfection assays for
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immunofluorescence or electron microscopic analyses SIL was added immediately after
transfection until fixation 24h later.
Amplification of HCV sequences from patients
HCV genomes were amplified in two fragments by RT-nested PCR from total RNA purified
from the serum of two patients before and after SIL therapy. Sequence data of both patients
were deposited in GenBank with following IDs: JQ914271 - patient A before SIL treatment,
JQ914272 - patient A after SIL treatment, KC155254 - patient A 21 months after cessation
of SIL therapy, JQ914273 - patient B before SIL treatment, JQ914274 - patient B after SIL
treatment. Primer sequences and protocols for RNA purification and RT-PCR are given in
Supplementary Materials and Methods. Written informed consent was obtained from both
patients. No donor organs were obtained from executed prisoners or other institutionalized
persons.
Results
SIL inhibits replication of HCV genotype 1b but not genotype 2a
To elucidate the MOA of SIL, we defined which part of the HCV lifecycle was primarily
inhibited by the drug. We first determined the SIL sensitivity of persistent subgenomic
reporter replicons of genotype 1b (Luc/neo Con1) and 2a (Luc/neo JFH1) mimicking
chronic HCV infection (Fig. 1A, B). Luc/neo Con1 replication was strongly inhibited by
SIL, whereas Luc/neo JFH1 replication was not affected (Fig. 1B), in line with recently
published data (11) and in absence of cytostatic effects of the drug (Fig. 1D). Similar results
were obtained upon transient transfection of luciferase replicons of the same isolates (Fig.
1A, C). In contrast and in agreement with previous reports, Silibinin (SbN) had no specific
impact on HCV RNA replication of Con1 or JFH1 ((11); Fig. S1). Since replicons based on
isolate JFH1 replicated much more efficiently in cell culture compared to Con1 (12) we
tested SIL sensitivity of JFH1 replicons harboring a chimeric 5′UTR or/and X-tail,
replicating with comparable efficiency (5′UTR or X-tail Con1) or even less efficiently
(5′UTR/X-tail Con1) than Con1 (Fig. 1E, (12). However, none of the replicons bearing the
JFH1 nonstructural protein coding sequence were inhibited by SIL treatment (Fig. 1F),
suggesting that JFH1 RNA replication is intrinsically unresponsive to SIL treatment. We
also found no significant impact of SIL on infection of a chimeric reporter virus (JcR-2a,
Fig. 1A, C (13)), arguing against a substantial inhibition of HCV gt2a entry and replication
by SIL. The data demonstrate a strong inhibition of persistent and transient HCV genotype
1b RNA replication by SIL and little impact on replication or infection of genotype 2a in
cell culture.
Selection for SIL resistance in vitro
We next selected gt1b replicon cells for resistance to SIL in vitro and obtained a few cell
clones with persistent HCV replication in presence of SIL. Sequence analysis of RT-PCR
amplicons identified seven mutations (Fig. 2A), which were conserved in at least one of
eight SIL resistant replicon cell clone (Table S1). All mutations were introduced
individually into a LucCon1 replicon (Fig. 1A) and analyzed for phenotypic effects on SIL
sensitivity and replication fitness. Only Q1914R in the C-terminal region of NS4B, present
in three SIL resistant replicon clones, significantly reduced HCV sensitivity to SIL (ca. 2fold
IC90; Fig. 2B, C; Table 1). Q1914R furthermore impaired replication fitness (Fig. 2D, E),
concordant with the high conservation of glutamine at this position across all HCV
genotypes, including isolate JFH1 (14).
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Collectively, the data indicate that SIL-resistant replicon clones were selected in vitro and a
mutation located in the C-terminal region of NS4B (Q1914R) conferred HCV gt1b
resistance to SIL.
Viral sequence analysis in a SIL-treated patient chronically infected with HCV
Since HCV resistance to SIL could be selected for in vitro, we asked whether SIL resistance
occurred in vivo. We focused on a male patient with chronic HCV genotype 1a infection
previously treated unsuccessfully with IFNα monotherapy, IFNα/RBV and pegIFNα/RBV.
The patient underwent extended right lobe liver transplantation and during the anhepatic
phase SIL therapy was initiated with 20mg/kg body weight/day based on previous reports
(4;8;15). After liver transplantation, viral titers dropped rapidly followed by a continuous
decrease of viral load until day 13 after onset of treatment (Fig. 3A). From day 18 to 27 viral
load increased back to basal level (viral breakthrough) suggesting the emergence of
resistance to SIL. To identify mutations potentially conferring SIL resistance, we amplified
and directly sequenced the viral genome before and after viral breakthrough in patient A
(Fig. 3B). Before SIL treatment we observed several polymorphisms (Fig. 3B, grey lines)
and a subpopulation of viral quasispecies carrying a deletion of the coding sequence of E2
and parts of E1 and p7 (nt 1204 to 2639) (Fig. 3C). After treatment the viral sequence lacked
polymorphisms and the subgenome was no longer detectable supporting the concept that the
viral quasispecies had passed a genetic bottleneck followed by selection of SIL resistant
variants. However, seven novel and conserved mutations exclusively within the
nonstructural proteins emerged: G963S (NS2), P/T1112S (NS3), F1809L, D1939N, T1946A
(NS4B), E2265D (NS5A) and V2431I (NS5B) (Fig. 3B, black lines, Table S2).
In summary, we analyzed a patient with viral breakthrough under SIL treatment, revealing
seven conserved mutations potentially contributing to SIL resistance.
Two mutations in NS4B identified in vivo contribute to SIL resistance
To characterize phenotypic effects of mutations identified in patient A, we used a highly cell
culture adapted variant of the HCV genotype 1a isolate H77, termed H77S (16) (Fig. 4A).
Replication fitness and SIL sensitivity of the H77S reporter replicon was similar to LucCon1
(Fig. 4D, 4B, Table 2). We chose F1809L, D1939N and E2265D for further phenotypic
analysis due to their high degree of conservation or because they matched to the SIL
resistance profile of HCV isolates in cell culture (Table S2). G963S was excluded since NS2
is not required for RNA replication (17). T1946A was already present in H77S, whereas
V2431I was found in the SIL sensitive isolate Con1 (Table S2). Mutations chosen for
phenotypic analysis of SIL resistance were introduced individually and in combinations into
the H77S reporter replicon (Fig. 4A) and analyzed for SIL sensitivity (Fig. 4B, C; Table 2)
and replication fitness (Fig. 4D, E). Mutation D1939N located in the C-terminal region of
NS4B significantly reduced SIL sensitivity of H77S (ca. 1.7fold IC90, Fig. 4C; Table 2),
accompanied by a significant impairment of replication fitness (Fig. 4E). F1809L slightly
reduced SIL sensitivity but significantly increased replication fitness (Fig. 4E). Interestingly,
double mutant F1809L+D1939N was less sensitive to SIL than the single mutants (ca.
2.5fold IC90; Fig. 4C, Table 2), arguing for a contribution of both NS4B mutations to SIL
resistance in the examined patient. Replication fitness was furthermore restored in the
double mutant F1809L+D1939N compared to the D1939N single mutant (Fig. 4E)
suggesting that the F1809L mutation compensated for the fitness cost associated with
D1939N. NS5A mutation E2265D had no impact on the resistance to SIL, neither
individually nor in combination (Fig. 4C, Table 2). The involvement of F1809L+D1939N in
SIL-resistance was supported by sequence analysis of viral genomes 21 months after
cessation of SIL therapy, since both positions were found reverted, in contrast to T1946A,
E2265D and V2431I (Fig. 3D). Additional reversion were found at positions 1112 in NS3
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and 963 in NS2. However, mutation P1112S did not contribute to SIL resistance in vitro,
neither as a single mutation introduced in the H77S replicon, nor in combination with
F1809L+D1939N (data not shown). Cumulatively, phenotypic analysis of mutations
identified in vivo supported a mechanism of action of SIL involving NS4B.
SIL does not affect NS4B self-interactions but probably interferes with NS4B-NS3/4A
interactions
NS4B is primarily involved in inducing membrane alterations known as the membranous
web which harbors the viral replication complex (18). Previous work suggests NS4B having
a complex membrane topology (Fig. 5A, reviewed in (14)). While position 1809 is located
in a proposed short ER-luminal loop between predicted transmembrane segments 1 and 2
(TM1 and 2), both major mutations conferring SIL resistance mapped to the C-terminal
region of NS4B. Interestingly, substitutions Q1914R and D1939N are located in a region of
amphipathic α-helices which are proposed to be embedded in the membrane interface and to
point to the cytosol, thereby providing a potential platform for protein-protein interactions
(Fig. 5A,B, (19)). Indeed, recent studies have delineated the functional importance of the
NS4B C-terminal mediated by homo- and heterotypic interactions between N- and C-termini
of NS4B (19–21). We employed a fluorescence resonance energy transfer (FRET)-based
assay described earlier (21) to address whether SIL affected self-interaction of NS4B (Fig.
5C). However, SIL had no effect on FRET efficiency, suggesting that SIL did not interfere
with NS4B oligomerization. Interactions of NS4B with other HCV nonstructural proteins
have been reported as well (reviewed in (14)). We therefore generated chimeric replicons
based on the SIL resistant JFH1 isolate, replacing parts of the nonstructural protein coding
region by homologous sequences of the SIL sensitive isolate Con1 (Fig. 5D), to analyze
which parts of the coding region transferred SIL sensitivity. Exclusive exchange of the
NS4B sequence of JFH1 significantly increased SIL sensitivity of the resulting chimera
compared to JFH1, but sensitivity did not reach the level of Con1 (NS4B Con1, Fig. 5E,F).
We then added the NS3/4A and/or the NS5A coding sequences of Con1 (Fig. 5D). The
construct harboring the NS4B and NS5A sequence of Con1 was not replication competent,
as well as a replicon containing only NS3/4A of Con1 (NS4B-5A Con1, NS3/4A Con1,
respectively; Fig. S3). However, SIL sensitivity of the chimeric replicons NS3-4B Con1 and
NS3-5A Con1 was identical to Con1 (Fig. 5D–F), suggesting that NS3/4A is an additional
important determinant of SIL response and arguing against a major contribution of NS5A.
SIL alters membranous web morphology
NS4B as well as NS3 have been described to induce membrane alterations (22) and the
interaction between both proteins might critically contribute to the formation of functional
HCV replication sites. These correspond to accumulations of vesicular structures (18),
mainly composed of double membrane vesicles (DMVs) (13). To address a potential
interference of SIL on the biogenesis of virus induced membrane alterations we transiently
expressed NS3-5B from Con1 or JFH1 in Huh7-T7 cells and analyzed the impact of SIL
treatment on the membranous web. SIL treatment had no impact on the distribution of
NS4B, NS3 and NS5A and did not change the degree of colocalization of these proteins
(Fig. S4 and S5). We also found no alterations in intracellular PI4P levels, suggesting that
SIL does not affect the activation of PI4KIIIα, an essential host factor of HCV replication
((13), Fig. S6). However, ultrastructural examination revealed that in cells expressing
NS3-5B of the Con1 isolate and treated with SIL, most of the vesicles observed were multi-
membrane vesicles (MMVs) and no longer DMVs (Fig. 6A,B), suggesting that SIL indeed
modulated the morphology of viral replication sites. In contrast, SbN had no impact on the
proportion of MMVs, confirming the specificity of the changes caused by SIL (Fig. S8).
Importantly, the morphology of membrane alterations induced by the SIL resistant genotype
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1b mutant Q1914R and by the resistant JFH1 isolate was not affected by SIL, supporting the
assumption that SIL indeed acts by disturbing viral replication sites (Fig. 6A,C and Fig. S7).
Collectively these data suggest that SIL treatment affects the morphogenesis of viral
replication sites by targeting NS4B, probably by modulating a critical interaction with
NS3/4A.
Discussion
The mechanisms by which SIL inhibits HCV infection in vivo are currently under debate.
Previous studies observed a direct inhibition of the viral polymerase in vitro by SIL and SbN
(10;11;23), suggestive for the mechanism in targeting RNA replication. However, our data
confirm that inhibition of viral RNA replication indeed is the primary MOA of SIL, but
implicate that NS4B is a candidate target: First we identified in vitro and in vivo mutations
in NS4B conferring partial SIL resistance. Second, SIL modulated the ultrastructure of
genotype 1b membrane alterations induced by the viral nonstructural proteins, which are
mainly mediated by NS4B (22), but not those generated by gt2a or by a SIL resistant gt1b
variant. Third, the NS4B and NS3/4A coding sequence of SIL sensitive isolate Con1
rendered resistant JFH1 fully sensitive to SIL. Taken together, these results suggest that the
antiviral activity of SIL is at least in part mediated by NS4B, probably by targeting an
interaction with NS3/4A. A critical interaction between NS3 and NS4B has already been
suggested by a previous study, based on genetic evidence (24). The fact that we identified
mutations conferring SIL resistance only in NS4B might simply reflect restrictions of the
isolates included in this study and clearly does not exclude potential alternative sites in NS3
conferring resistance to SIL in other HCV isolates.
NS4B is the key factor inducing membrane alterations harboring the HCV replication sites,
which mainly consist of DMVs and to a lesser extend MMVs (13;20). The biogenesis of
these vesicular structures is poorly defined, but they are believed to be generated by a
concerted action of the nonstructural proteins, with NS4B as the main actor (22). The fact
that SIL strongly reduced the number of DMVs and triggered the formation of MMVs
therefore argues for an interference with the morphogenesis of viral replication sites.
Mutations conferring resistance were mainly located at the C-terminal amphipathic α-
helices (Fig. 5A), and affected conserved residues facing the cytosol (Fig. 5B). Those sites
could provide a platform for the interaction with other NS-proteins, like NS3/4A or with
host factors. Although our studies suggest that SIL might affect a critical NS4B interaction
with NS3/4A, we cannot exclude that SIL in addition impacts on interactions of other NS
proteins or host factors. The membrane activity reported for Silibinin (25) might also
contribute to the antiviral action of SIL, due to the tight membrane association of all viral
proteins. The precise mechanism of action of SIL remains to be determined. However, SIL
is not the first drug reported to target NS4B (reviewed in (26)), but resistance profiles and
suggested MOAs of other classes of NS4B inhibitors suggest that SIL represents a novel
type with a unique mode of action.
In contrast to other studies (10;11), we found no evidence for a substantial inhibition of
genotype 2a HCVcc infection by SIL. Still, we might have missed effects on entry due to
differences in the experimental design. The fact that mutation G963S at a highly conserved
position in NS2 was found after therapy but reverted back later suggests that NS2 might be a
target of SIL too. Such additional MOAs complementing inhibition of RNA replication
might also explain cure or at least absence of viral breakthrough in SIL monotherapy
(3;4;27;28) due to a higher barrier to resistance.
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The limited data on SIL therapy outcomes include sustained virological response (3–7),
initial suppression of viral replication followed by rebound (relapse or breakthrough, patient
A, (5;6)) and non-response (patient B, Fig. S2 (6;15)). Rutter et al. suggested low viral load
as the most valuable predictor of treatment response in their study (6). This might account
for successful therapies post LTx (3;4), since a small pool of virus variants at the onset of
therapy limits the chance to select for resistance. The main determinant for successful SIL
monotherapy after LTx might therefore be the barrier to resistance of the HCV quasispecies
in a patient. In the case of patient A, two mutations in highly conserved residues in NS4B
seemed to be sufficient for viral breakthrough; in case of other isolates, more mutations
might be required or the fitness costs associated with these mutations might be higher. Our
data furthermore indicate that SIL might not be effective in genotype 2 since we found no
inhibition of RNA replication of genotype 2a isolate JFH1. Interestingly, this is corroborated
by two clinical reports about nonresponse of genotype 2 patients to SIL ((29) and S.
Beinhardt, personal communication). However, larger patient cohorts will be required to
clarify determinants of treatment failure, particularly since a second gt1a patient treated with
SIL (patient B) did not respond to SIL therapy, without having obvious alterations in the
NS4B sequence (Fig. S2)
In conclusion, our data indicate that SIL is an efficient inhibitor of HCV RNA replication at
least in part by targeting NS4B. The emergence of resistance in vivo and in vitro suggests
that SIL should not be used in monotherapy. Although it seems unlikely that SIL will
become a major drug in HCV therapy, it represents a promising component of future
combination therapies particularly in difficult-to-treat patient cohorts, due to its novel mode
of action and unique resistance profile.
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r.l.u Relative light units
SIL Legalon-SIL
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HCV Hepatitis C virus
IFNα Interferon alpha
IRES Internal ribosome entry site
i.v Intravenously
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LTx Liver transplantation
DAA directly acting antiviral
EM electron microscopy
DMV double membrane vesicle
MMV multi membrane vesicle
MOA mode of action
PI4P Phosphatidylinositol 4-phosphate
PI4KIIIα Phosphatidylinositol 4-phosphate kinase type III α
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Figure 1. SIL sensitivity of different HCV genotypes
(A) Scheme of viral genomes analyzed for SIL sensitivity. Luciferase: firefly luciferase, R-
Luc: renilla luciferase, PI: poliovirus IRES, EI: Encephalomyocarditisvirus IRES, NTR:
nontranslated region, 2A: 2A peptide-coding region of foot-and-mouth disease virus. (B)
Huh7-Lunet cells harboring a persistent Luc/neo replicon of gt1b (Con1) or 2a (JFH1) were
treated for 44h with the indicated concentrations of SIL. Mean values and SD from a
representative experiment (n=2). (C) Replication or infection efficiency of different HCV
genotypes after SIL-treatment. Huh7-Lunet cells were transfected or Huh7.5 cells infected in
triplicates with the respective replicons or JcR-2a virus and treated with indicated
concentrations of SIL. Mean and SD of one representative experiment (n=2). (D) Impact of
SIL treatment on Huh7-Lunet cell proliferation. Data represent mean and SD of triplicate
values of two independent experiments. (E, F) Replication fitness (E) and SIL sensitivity (F)
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of different HCV subgenomic replicons of gt1b, gt2a and gt2a replicons with chimeric
5′UTR or X-tail derived from gt1b (12). Mean and SD from one representative experiment
(n=2).
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Figure 2. Analysis of SIL resistance in vitro
(A) Schematic representation of conserved mutations found in eight SIL resistant Con1
(gt1b) replicon cell clones by direct sequencing of RT-PCR amplicons (dashed lines). (B)
Impact of mutations identified in SIL resistant replicon cell clones on SIL sensitivity of the
LucCon1 replicon (Fig. 1A). Mean and SD of a representative experiment (n=3). (C)
Statistical analysis of SIL sensitivity of mutant Q1914R compared to LucCon1 at 118μM
SIL. Mean values and SD from three independent experiments. (D) Replication fitness of
LucCon1 replicons containing the indicated mutations identified after SIL selection. Mean
and SD of one representative experiment (n=3). (E) Statistical analysis of replication fitness
of LucCon1 replicons. Mean and SD of three independent experiments. (*) p<0.05 (**)
p<0.01 (***) p<0.001
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Figure 3. Analysis of viral sequences in a SIL-treated patient
(A) Course of HCV RNA levels [IU/ml serum] in patient A chronically infected with HCV.
LTx indicates the time of liver transplantation (day0). (B) Schematic representation of
mutations identified in patient A following viral breakthrough during SIL treatment by
direct sequencing at day −113 (4.3×105 IU/ml) and 45 (3.2×105 IU/ml). Black lines indicate
new and conserved mutations found after SIL therapy. Grey lines represent polymorphisms
found before LTx disappearing after viral breakthrough. (C) Scheme of a subgenome found
in a subpopulation of viral quasispecies of patient A before SIL treatment. (D) Changes in
the HCV sequence of patient A 21 months after cessation of SIL therapy compared to the
sequence at day 45. New polymorphisms are indicated by grey lines, reversions to the pre-
treatment sequence are underlined.
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Figure 4. Phenotypic analysis of mutations found after viral breakthrough during SIL treatment
(A) Scheme of the gt1a reporter replicon based on isolate H77 and containing five cell
culture adaptive mutations indicated by asterisks (H77S, (16)). (B) Impact of mutations
identified in vivo on SIL sensitivity of mutant LucH77S replicons as indicated. Mean and
SD from a representative experiment (n=3). (C) Statistical analysis of SIL sensitivity of
mutant LucH77S replicons compared to the wildtype at 118μM SIL. Mean and SD of three
independent experiments. (D) Replication fitness of mutant LucH77S replicons. Mean and
SD of one representative experiment (n=3). (E) Statistical analysis of the replication fitness
of mutant H77S replicons compared to LucH77S wildtype. Mean and SD of three
independent experiments. (ns) not significant (**) p<0.01 (***) p<0.001
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Figure 5. Position of SIL-resistance mutations in NS4B and analyses of NS4B self-interactions
and SIL sensitivity of chimeric replicons
(A) Predicted membrane topology of NS4B and localization of mutations contributing to
SIL resistance in vivo (red stars) or in vitro (blue star). AH1, AH2, amphipatic helices;
TM1-4 predicted transmembrane regions; H1, H2 C-terminal α-helices (14). (B) Tentative
membrane location of the two C-terminal amphipathic α-helices H1 and H2 ((19), PDB
entry: 2KDR) and orientation of amino acid side chains at position 1914 (upper panel) and
1939 (lower panel), respectively. Hydrophobic residues are shown in light gray, polar
residues in yellow, Gln in magenta, His in cyan and basic and acidic residues are blue and
red, respectively. Figures were generated from structure coordinates using VMD (http://
www.ks.uiuc.edu/Research/vmd/).
(C) Influence of SIL on homo- and heterotypic NS4B self-interactions. Full-length (4B), C-
terminal (C) or N-terminal (N) constructs fused to Cerulean cyan fluorescent protein (CFP)
or Venus yellow fluorescent protein (YFP) were cotransfected into US-OS cells and
analyzed for fluorescence resonance energy transfer (FRET) in presence and absence of SIL.
The results are shown as box plots representing 56 measurements performed under each
condition. (D) Schematic representation of the nonstructural protein regions of chimeric
replicon constructs. Portions of the SIL-resistant isolate JFH1 and the SIL-sensitive isolate
Con1 are given in black and white, respectively. (E) SIL sensitivity of chimeric reporter
replicons and parental constructs as indicated in (D). Mean and SD of triplicate values from
a representative experiment (n=3). Note that chimeras NS4B-5A Con1 and NS3-4A Con1
were not replication competent (Fig. S3). (F) Statistical analysis of SIL resistance of
replicon chimeras compared to LucJFH1 at 118μM SIL. Mean values and SD from two
independent experiments.
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Figure 6. Impact of SIL on NS4B-induced membranous web morphology
(A) Percentage of multi-membrane vesicles (MMV) in Lunet-T7 cells transfected with pTM
plasmids encoding NS3-5B of HCV JFH1, Con1 or Con1 Q1914R, respectively, in presence
and absence of SIL (n=60). (B,C) Ultrastructural analysis of the morphology of the
membranous web (MW) in presence and absence of SIL upon expression of NS3-5B of
isolate Con1 (B) or Con1 Q1914R (C).
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Table 1
Mutations identified in replicon cell clones after SIL-selection and corresponding IC90
Mutation Protein (aa) IC90 [μM SIL] 95% confidence interval FrequencyA
Con1WT 92 67 to 126
I1044T NS3 (18) 94 58 to 153 2/8
T1048A NS3 (22) 85 67 to 108 1/8
V1681A NS4A (24) 89 69 to 114 1/8
S1827T NS4B (116) 94 59 to 150 2/8
Q1914R NS4B (203) 191 144 to 254 3/8
T2036A NS5A (64) 102 80 to 130 1/8
S2925G NS5B (506) 85 68 to 107 1/8
ANumber of SIL-resistant replicon cell clones containing the mutated sequence (n=8)
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Table 2
SIL sensitivity of H77S replicons containing single or multiple mutations identified in patient A after SIL
therapy
Mutation Protein IC90 [μM SIL] 95% confidence interval
H77S 104 81 to 133
F1809L NS4B 137 102 to 184
D1939N NS4B 172 129 to 228
F1809L + D1939N NS4B 252 167 to 381
E2265D NS5A 102 86 to 120
F1809L + D1939N + E2265D NS4B+NS5A 263 186 to 370
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